Submit Manuscript  

Article Details

Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Mutation: First Line Treatment and Beyond

[ Vol. 14 , Issue. 2 ]


Danilo Rocco, Ciro Battiloro , Luigi Della Gravara and Cesare Gridelli*   Pages 120 - 128 ( 9 )


Background: Lung cancer is the leading cause of cancer mortality, being responsible for more than 1.6 million deaths each year worldwide and non-small-cell lung cancer (NSCLC) accounts for approximately 85% of lung cancers; moreover, 10 to 15% of all NSCLCs harbor EGFR (epidermal growth factor receptor) activating mutations, being suitable for EGFR-Tyrosine Kinase Inhibitors (TKI) molecular targeted therapy. However, EGFR+ NSCLCs gain acquired resistance to these agents, representing one of the key challenges for modern precision oncology.

Objective: Therefore, this paper aims to provide an extensive state of the art review, alongside with hints about future perspectives.

Conclusion: To date, in the light of the data from the FLAURA study, osimertinib represents the best first-line option in NSCLC patients with EGFR activating mutations; EGFR-TKI plus chemotherapy combination therapies, even though interesting, must still be considered investigational.


Combination therapy, EGFR, NSCLC, Osimertinib, T790M, TKI.NSCLC, EGFR, TKI, T790M, Osimertinib, Combination therapy


Division of Pulmonary Oncology , Azienda Ospedaliera Dei Colli Monaldi, Naples, Division of Pulmonary Oncology , Azienda Ospedaliera Dei Colli Monaldi, Naples, Luigi Vanvitelli University, Caserta, Division of Medical Oncology, AORN Giuseppe Moscati, Avellino

Read Full-Text article